Climb Bio Inc
CLYM1.700USD
+0.250+17.22%
Market hours （ET）Quotes delayed by 15 min
114.86MMarket Cap
LossP/E TTM
More Details of Climb Bio Inc Company
Climb Bio, Inc., formerly Eliem Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial.
Company Info
Ticker SymbolCLYM
Company nameClimb Bio Inc
IPO dateAug 10, 2021
CEODr. Aoife M. Brennan
Number of employees17
Security typeOrdinary Share
Fiscal year-endAug 10
Address20 William Street
CityWELLESLEY HILLS
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02481
Phone18668572596
Websitehttps://climbbio.com/
Ticker SymbolCLYM
IPO dateAug 10, 2021
CEODr. Aoife M. Brennan
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. Bo Cumbo
Mr. Bo Cumbo
Independent Director
Independent Director
--
--
Ms. Kim Cobleigh Drapkin, CPA
Ms. Kim Cobleigh Drapkin, CPA
Independent Director
Independent Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. Bo Cumbo
Mr. Bo Cumbo
Independent Director
Independent Director
--
--
Ms. Kim Cobleigh Drapkin, CPA
Ms. Kim Cobleigh Drapkin, CPA
Independent Director
Independent Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
46.49%
Pontifax Venture Capital
7.70%
Access Industries, Inc.
7.41%
BlackRock Institutional Trust Company, N.A.
3.10%
Cantor Fitzgerald, L.P
2.96%
Other
32.32%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
46.49%
Pontifax Venture Capital
7.70%
Access Industries, Inc.
7.41%
BlackRock Institutional Trust Company, N.A.
3.10%
Cantor Fitzgerald, L.P
2.96%
Other
32.32%
Shareholder Types
Shareholders
Proportion
Venture Capital
54.93%
Investment Advisor
12.36%
Hedge Fund
11.49%
Corporation
7.41%
Research Firm
3.67%
Investment Advisor/Hedge Fund
2.47%
Individual Investor
0.67%
Bank and Trust
0.05%
Pension Fund
0.03%
Other
6.93%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
168
62.90M
93.07%
-4.49M
2025Q1
169
68.90M
101.99%
-1.34M
2024Q4
155
67.64M
100.63%
-51.77K
2024Q3
127
63.79M
95.46%
+1.90M
2024Q2
91
59.36M
99.92%
+31.16M
2024Q1
87
26.17M
94.38%
-3.33M
2023Q4
91
26.16M
95.54%
-3.35M
2023Q3
92
25.94M
95.83%
-3.54M
2023Q2
93
25.92M
96.06%
-3.17M
2023Q1
92
25.90M
96.01%
-3.10M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
31.42M
46.49%
--
--
Mar 31, 2025
Pontifax Venture Capital
5.21M
7.7%
+5.21M
--
Mar 31, 2025
Access Industries, Inc.
5.01M
7.41%
--
--
Aug 14, 2024
BlackRock Institutional Trust Company, N.A.
2.10M
3.1%
-10.56K
-0.50%
Mar 31, 2025
Cantor Fitzgerald, L.P
2.00M
2.96%
+1.35M
+207.37%
Mar 31, 2025
Citi Investment Research (US)
1.85M
2.74%
+1.83M
+8039.18%
Mar 31, 2025
The Vanguard Group, Inc.
1.50M
2.22%
-3.70K
-0.25%
Mar 31, 2025
Affinity Asset Advisors LLC
1.50M
2.22%
+1.00M
+200.00%
Mar 31, 2025
Kynam Capital Management LP
1.05M
1.55%
+500.00K
+91.41%
Mar 31, 2025
Deep Track Capital LP
1.04M
1.54%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Neuroscience and Healthcare ETF
0%
iShares Russell 2000 Value ETF
0%
View more
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
iShares Micro-Cap ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Neuroscience and Healthcare ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
